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Objectives: This investigation on a homogenous cohort of young adult Caucasian type 1 diabetic (IDDM)
patients (1) aimed at studying the occurrence of low bone mineral density (BMD) at an early stage prior to
menopause (i.e., during the first decade after peak bone mass) and (2) elucidating the possible mechanisms
underlying IDDM-induced bone complication.
Methods: Twenty-seven female patients with insulin-treated and well-controlled diabetes, without renal
complications, and 32 well-matched healthy controls, aged between 30 and 40 years and fulfilling rigorous
inclusion criteria to minimize bone-confounding factors, were enrolled. Areal BMD was evaluated by dual
energy X-ray absorptiometry at axial (lumbar spine) and appendicular (femur) sites, using diagnostic WHO
reference (T-scores). Osteoblast functions, bone metabolism, related key minerals, and 2 osteoclast-stimulating
calciotropic hormones regulating their serum levels were assessed biochemically.
Results: The number of cases with low BMD (T-score below21.1 SD) was almost 2-fold greater (p, 0.01)
in the IDDM group. BMD was significantly lower in this group for 3 lumbar sites (p , 0.01) and femur Ward’s
triangle (p , 0.05). Bone formation was reduced, as evidenced by the suppressions of osteocalcin (OC; p ,
0.01) and IGF-I (p, 0.001). However, bone alkaline phosphatase (bALP) was induced (p, 0.01), in contrast to
what is usually observed in cases of reduced bone formation. Correlated total ALP activity was also significantly
increased. There was no change in the specific marker of bone resorption (urinary deoxypyridinoline). Serum
calcium was significantly elevated, particularly after adjustment for albumin (p , 0.001), despite lower
1,25(OH)2D3 (p , 0.001) and no elevation of PTH. All significant bone-related biochemical changes were
significantly correlated with glycosylated hemoglobin, a clinical indicator of long-term glycemic control,
indicating a direct effect of the disease.
Conclusions: Bone loss in the IDDM group results from a decrease in bone formation rather than an increase
of bone resorption. The induction of bALP is indicative of impaired osteoblast differentiation and maturation,
which delayed (down-regulated) later stages of matrix mineralization, as evidenced by lower OC and BMD.
Address reprint requests to: Priscilla Masse´, PhD, Department of Human Nutrition, University of Moncton, Moncton, NB, E1A 3E9 CANADA. E-mail:
priscille.masse@umoncton.ca
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Abbreviations: 25(OH)D3 5 25-hydroxycholecalciferol, 1,25(OH)2D3 5 1,25-dihydroxycholecalciferol, ACR 5 urinary albumin/creatinine ratio, ALP 5 alkaline
phosphatase, bALP 5 bone-specific alkaline phosphatase, BMD 5 bone mineral density, BMI 5 body mass index, Dpd 5 free deoxypyridinoline, HbA1c 5 glycosylated
hemoglobin, IGF-I 5 insulin-like growth factor I, iPTH 5 intact parathyroid hormone, OC 5 osteocalcin.
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INTRODUCTION
Bone studies on the effect of insulin-dependent type 1
diabetes mellitus (IDDM) in young adult women at a time in
life following the attainment of peak bone mass are limited. In
most cases, diabetic patients under investigation were already
affected by complications of the disease or investigated at a
time when peak bone mass was not attained (e.g., during
childhood and adolescence). Although there seems to be a
consensus in the literature on IDDM-induced low bone mineral
density (BMD) [1,2], published results on the narrower age and
gender spectrums of interest in the present study are
conflicting. An increased incidence of low BMD has been
associated with IDDM [3–6], but some investigators have not
found significant reductions [7–9], including Rozadilla et al.
[10], who studied young IDDM patients at an age of interest,
that is, after adolescence, when peak bone mass was almost
theoretically achieved. This controversy could be explained,
among other factors, by the heterogeneity of the study
populations (age, [pre]menopause, gender, mixed ethnicity,
duration and metabolic control of the disease, i.e., presence of
complications, type of diabetes) as revealed by a recent meta-
analysis and literature review studies [1,2].
The fundamental feature of bone in IDDM patients seems
to be the retardation of remodeling, primarily due to a reduced
bone formation [11–13]. This outcome could derive from a
decrease in the number and functions of osteoblasts (bone
formation cells). Osteoblasts have receptors for insulin and
insulin-like growth factor (IGF-I; insulin dependent), both of
which stimulate the activity and replication of these cells [14].
Although the levels of insulin necessary for this effect are
unknown, the below-normal concentrations at the preclinical
stage of IDDM are likely inadequate. Data from Kemink et al.
[12] suggested that low osteoblast-stimulating IGF-I may be
responsible for osteopenia in IDDM and indicative of a cellular
maturation defect and lowered bone formation. Reduced serum
IGF-I values have been reported in poorly controlled patients
[15]. According to Bouillon et al. [15], the most mature
osteoblast marker, osteocalcin (OC), is decreased in all types
of diabetes, irrespective of age. A reduction in the renal
synthesis of 1,25-dihydroxycholecalciferol [1,25(OH)2D3] has
been found in diabetic patients with poor glycemic control and
a tendency for acidosis [16,17]. A decline in this vitamin
hormone has a notable repercussion on bone metabolism and
integrity.
Since the involvement of bone in diabetes is of ambiguous
pathogenicity and factors involved are not well defined and
remain controversial, bone studies must be designed to
examine this tissue at both the cellular and matrix (collagen)
levels and to analyze concomitantly serum mineral concentra-
tions, their pertinent regulatory hormones, and related factors.
Among these factors, iron is certainly of particular interest. In
bone metabolism, iron has a double role as the cofactor in
reactions of the hydroxylation of prolyl/lysyl amino acid
residues of bone collagen and of the renal hydroxylation of 25-
hydroxycholecalciferol [25(OH)D3] to its active form
[1,25(OH)2D3] [18]. Pair feeding an iron-deficient diet to rats,
in a recent histomorphometric study, Katsumata et al. [19]
found significant reductions in serum concentrations of
1,25(OH)2D3, IGF-I, and OC.
The need to better understand the effects of IDDM on bone
stems in part from the risk of osteoporosis and related fractures
later in life. In a 12-year prospective study, Krakauer et al. [20]
showed that radial bone loss continued at the expected rate in
IDDM patients. But there is disagreement on this issue. From
their prospective study, Kayath et al. [6] concluded that
diabetic osteopenia, despite being a complication of high
prevalence in IDDM, was nonprogressive in most patients after
the attainment of peak bone mass.
The present study targeted young adult female IDDM
patients during the first decade after the achievement of peak
bone mass (age category 30–40 years). Its first objective was to
evaluate the occurrence of bone loss at an early stage, prior to
menopause. The second objective was to shed light on the
underlying mechanisms by studying bone density and
metabolism using densitometry combined with diverse specific
biochemical markers that aimed at assessing osteoblast
functions, bone turnover markers, key bone minerals, and 2
osteoclast-stimulating calciotropic hormones regulating their
serum levels. The study protocol was designed to recruit
rigorously IDDM patients and well-matched healthy controls
to form a homogenous cohort of Caucasian women to
minimize important bone confounders. Women were targeted
because they are more at risk of osteoporosis than men because
of high nutritional needs during pregnancy and lactation.
SUBJECTS AND METHODS
Caucasian women with insulin-treated and well-controlled
type 1 diabetes, aged between 30 and 40 years, were referred
by Diabetes Clinics located in New Brunswick, Canada. Age-
and ethnicity-matched healthy women volunteered to partic-
ipate as controls in response to public advertising. Eligibility
criteria were specified. An initial screening of all respondents
was conducted over the phone to exclude noneligible subjects,
smokers and vegetarians. Only eumenorrheic women (non-
pregnant, nonlactating, and not taking oral contraceptives)
were eligible. The other criteria were to be nonobese (body
mass index [BMI] ,30 kg/m2), without a history of bone
fracture [21] or renal complication (in the case of diabetic
subjects), and not using regularly nutritive supplement and
medication (statins, corticosteroids, thiazide diuretics, anticon-
vulsive drugs, calcitonin, and diphosphonates) known to
interfere with bone metabolism.
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Women who met the inclusion criteria attended an initial
information meeting and signed a consent form. The research
protocol was approved by the Ethics Committee on Human
Research of the Universite´ de Moncton and by the review
boards of hospitals involved in the study. Subjects who
consented to enroll filled out a general questionnaire, which
included items on socioeconomic and reproductive character-
istics and medical history. Physical activity was estimated
using the scores from Elders et al. [22].
Anthropometric Measurements
Height was determined using a wall-mounted stadiometer.
Body weight was determined to within 100 g using a standard
beam platform balance scale detector (Bionetics, St-Laurent,
Que´bec, Canada). Subjects were weighed with indoor clothing
without shoes. BMI was calculated from measured body weight
(kg) and height (m) as weight/(height)2. Body frame size was
assessed by measuring wrist circumference [23]. Waist and hip
circumferences (cm) were measured to calculate the waist-hip
ratio [24], used as a general health status indicator.
Evaluation of Self-selected Diets
Subjects were asked to record their food intakes for 3
nonconsecutive days (including 1 weekend day) preceding
blood collection. Written instructions were provided to all of
them and explained by a registered dietitian to maximize
completeness and accuracy of recording. Subjects were asked
not to modify their regular food intakes while recording and to
record all foods and beverages immediately after consumption.
Each dietary record was checked for completeness by the
same dietitian in the presence of each subject. Daily energy and
pertinent nutrient intakes were determined using Food Processor
SQLH (version 9.5, 2004, Esha Research, Salem, OR). Estimated
intakes of each nutrient were averaged (n5 3 d) to compare the 2
groups of women and to assess the nutritional adequacy of their
diets with respect to current dietary reference intakes [25].
Retrospective dietary intakes of calcium during periods of high
calcium nutritional needs (adolescence, pregnancy, and lacta-
tion) and caffeine consumption were estimated using a frequency
questionnaire based on the best food sources of calcium and most
common caffeine-containing beverages consumed, respectively,
assuming standard portions explained by the dietitian.
Determination of BMD
BMD of the anteroposterior lumbar spine and standard
femoral sites was determined at the Georges-L.-Dumont
Hospital by dual energy X-ray absorptiometry (DEXA; Lunar
Corp., Madison, WI), after blood and urine collection. The
instrument was calibrated daily according to the manufactur-
er’s instructions. All measurements were carried out on the
same machine by the same operator, and the results were
analyzed on the same software. Areal BMD (g/cm2) was
measured at diverse lumbar (L) and femoral sites (L1 to L4,
L1–L2, L1–L3, L1–L4, L2–L3, L2–L4, L3–L4, femur neck,
Ward’s triangle, trochanter, and diaphysis). The BMD of the
femoral diaphysis, a predominantly cortical bone, was
determined by scanning the upper shaft of the proximal femur
below the intertrochanteric line. To take bone size into account
[26], apparent volumetric density (BMAD, in g/cm3) was
calculated for vertebrae (L) using the following equation:
BMAD 5 BMC/(Ap 3 w), where BMC is the bone mineral
content, Ap is the projected spinal area, and w is the vertebral
width [26]. Typical precision, expressed as coefficient of
variation, with our DEXA method in normal subjects was less
than 2% for all sites studied. Its accuracy (0.5%) was assessed
by bone simulation phantoms. According to the definition
established by World Health Organization (WHO) experts
[27], bone loss is diagnosed when the BMD value is between
1.0 SD and 2.5 SD below the average value (T-score) of the
peak bone mass of 30-year-old healthy adults, in the case of
osteopenia, and when the T-score is less than 22.5 SD in the
case of osteoporosis.
Biological Sample Collection and
Biochemical Analyses
Antecubital venous blood and urine samples were collected
from all subjects, in the morning and after an overnight fast, and
sent immediately to routine hospital laboratories according to
their procedures or kept frozen at 270uC in our laboratory until
analyses in cases of specialized tests. Blood used for serum
analyses was allowed to clot for 1 hour at 37uC and then
centrifuged at 2000 3 g for 10 minutes at 4uC. The metabolic
control of diabetes was evaluated by the determination of
glycosylated hemoglobin (HbA1c), a clinical indicator of long-
term glucose control. Kits from Stanbio Laboratory (Boerne, TX)
were used to assay urinary albumin and creatinine. Their ratio
(ACR) was calculated and used to assess renal status [28]. Blood
hemoglobin level and serum concentrations of albumin, calcium,
inorganic phosphorus, iron, magnesium, intact parathyroid
hormone (iPTH), and total alkaline phosphatase (ALP) were
determined by routine automated procedures. Values for serum
calcium were adjusted for albumin according to Berry et al. [29].
Plasma OC and bone-specific ALP (bALP), used as
markers of bone formation (to assess osteoblastic functions),
were analyzed using kits from Quidel Corporation (Mountain
View, CA). The osteoblast-stimulating insulin growth factor
(IGF-I) in circulation was also determined, using the method of
Donovan et al. [30]. Free deoxypyridinoline (Dpd), a collagen
end-metabolite commonly used as a marker of bone resorption,
was measured on nonhydrolyzed urine samples using a
competitive enzyme immunoassay (Metra Dpd, Quidel Cor-
poration, Mountain View, CA). Values were corrected for the
urinary concentration of creatinine in the sample. Plasma
Type 1 Diabetes–Induced Bone Complication
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25(OH)D3 and 1,25(OH)2D3 concentrations were measured by
a radioimmunoassay (ImmunoDiagnostic Systems, Boldon,
UK) and compared with reference values [31,32]. Iron,
involved as the cofactor in the hydroxylation of 25(OH)D3 to
1,25(OH)2D3, was determined using an automated colorimetric
technique (Vitros Fusion 5.1 Microslides, Ortho-Clinical
Diagnostics, Rochester, NY).
The interassay coefficient of variation for all assays was
less than 8%.
Statistical Analyses
Data were analyzed using InStat (version 2.0, 1998,
GraphPad Software, San Diego, CA). Descriptive statistics
were calculated, and normality was assessed. Variables were
analyzed accordingly, using Student 2-tailed unpaired t test or
nonparametric Mann-Whitney test. Relationships between
pertinent biochemical variables were analyzed using Pearson
or Spearman correlation coefficient (r) as appropriate. A value
of p # 0.05 was considered significant.
RESULTS
Among the 50 healthy women who responded to public
advertisings and the lists of IDDM patients who were referred
by the Diabetes Clinics, 32 and 27 subjects, respectively, met
all eligibility criteria and completed the study. The mean age
of each group, 34.8 and 36.9 years, respectively, was
comparable. Using HbA1c to confirm the diagnosis of diabetes
and its metabolic control revealed that the only marked
difference (p, 0.0001) between the 2 groups was the presence
of this disease, as expected (Table 1). IDDM was well
controlled according to this clinical indicator (only slightly
above the reference value of 7.5%), a prerequisite to
participate in the study. HbA1c values below 6.0% are found
in healthy, euglycemic persons and may be difficult to achieve
for persons with diabetes, even with intense insulin therapy.
Diabetic patients were diagnosed with IDDM since 19.8 years
on average. They were otherwise healthy, another inclusion
criteria, with normal serum albumin and iron concentrations,
and apparently without renal complications (as assessed by
ACR) and no diagnosis of anemia (a sign of a more advanced
stage of the disease and presence of irregular menstruations) as
assessed by hemoglobin level. The 2 groups were also
comparable for age at menarche, parity, and physical activity
(Table 1), as well as ethnicity, geographic region (latitude
46uN), and socioeconomic background (data not shown).
Height, body weight, and frame did not differ significantly.
None of the differences between groups in terms of dietary
intakes of interest were significant, including proline and
lysine, the 2 specific amino acids of the helical collagen
Table 1. Descriptive Characteristics of Subject Groups Pertinent to General Health and Nutritional Protein Status in Fulfillment of
Selection Criteria1
Reference Values2 Control Group Diabetic Group
Age, y — 34.8 6 4.1 36.9 6 3.3
Weight, kg — 68.3 6 8.3 68.4 6 12.6
Height, cm — 161 6 6 162 6 5
Body mass index, kg/m2 ,303 24.3 6 2.6 26.1 6 4.2
Waist–hip ratio, cm/cm ,0.843 0.78 6 0.05 0.80 6 0.07
Wrist circumference (cm) — 15.2 6 0.9 15.6 6 1.2
Body frame size 9.9–10.94 10.6 6 0.6 10.4 6 0.7
Diabetes duration, y — — 19.8 6 9.0
Glycosylated hemoglobin, % ,7.5 5.5 6 1.6 7.8 6 1.4****
Hemoglobin, g/100 mL .11.7 13.4 6 1.2 13.6 6 1.0
Serum albumin, g/100 mL .3.5 4.39 6 0.27 4.25 6 0.27
Urinary albumin, mg/L — 37.5 6 4.0 37.6 6 5.1
Urinary creatinine, mmol/L — 9.71 6 6.03 8.61 6 7.33
Urinary albumin/creatinine, mg/mmol ,2.85 0.46–1.16 0.51–1.40
Menarche, y — 13.0 6 1.4 13.4 6 1.7
Number of full-term pregnancies — 1.0 6 1.0 1.1 6 0.9
Number of years since last pregnancy — 6.3 6 4.3 9.4 6 6.3
Caffeine intake, mg/d — 96–261 163–377
Physical activity (score)6 — 10.8 6 2.8 9.3 6 3.0
1 Mean 6 standard deviation, except for urinary albumin/creatinine ratio and caffeine intake (95% confidence intervals).
2 Reference values from our laboratories, except where otherwise specified.
3 Gibson, 2005 [24].
4 Range values for medium body frame size (Lee and Nieman, 2007 [23]).
5 Canadian Diabetes Association, 2008 [28].
6 Elders et al., 1989 [22].
**** p , 0.0001.
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polypeptide chains (Table 2). Energy intakes were below the
estimated energy requirement for their age category, and
consequently, both groups did not meet their nutritional needs
for several nutrients, including those crucial for bone health,
such as calcium, vitamin D, and magnesium.
Fig. 1 shows the occurrence of combined cases of
osteopenia/osteoporosis (based on T-scores) in both groups.
Depending on bone site, the proportions varied markedly from
9%–45% in the diabetic group, compared with 4%–25% in
healthy controls. As shown in Fig. 1, the proportion of cases
was greater in the diabetic group for all sites, except for L2–L4
and L3–L4 for unknown reasons. When averaging all sites, the
number of cases (%) was almost 2-fold greater (p , 0.01) in
the diabetic group (23.4 vs. 12.1; 95% confidence intervals:
16.1–30.9 vs. 8.4–15.9). As shown in Fig. 2, the BMD of all
sites was lower in this group, and differences between groups
reached a significance level for 3 lumbar sites (L1, L2, and
L1–L2; p , 0.01) and femur Ward’s triangle (p , 0.05).
IDDM patients were 4 times more likely (p , 0.01) to be
osteopenic/osteoporotic (based on T-scores) at these apparent-
ly most sensitive sites as compared with healthy controls. It is
also worth noting that significant differences in BMD at
lumbar sites L1 and L1–L2 represent the least dense vertebra
(L1), as described by Mylonakis et al. [33].
No significant difference between groups was found for
femur diaphysis, predominantly cortical bone. Volumetric
BMAD (data not shown), which take into consideration the
size of vertebrae, showed similar results but did not add more
precision (no change in significance level) to the areal
measurements, in contrast to the findings of a previous study
on menopausal women [34] and the findings of Jergas et al. [35].
A striking biochemical finding, directly related to bone
metabolism, was observed in the diabetic group, that is, the
alteration in serum calcium homeostasis occurring indepen-
dently of the effect of the major calciotropic hormones,
1,25(OH)2D3 and PTH (Table 3). In effect, the elevation of
serum calcium, highly significant after adjusting for albumin
(p , 0.001), occurred despite a significantly lower plasma
1,25(OH)2D3 (p , 0.001) and no elevation of serum PTH
which was found to be inversely correlated with serum calcium
(p , 0.001) and with HbA1c (p , 0.01; Table 4). Hepatic
precursor 25(OH)D3 was unchanged and above the cutoff of
50 nmol/L established by Calvo and Whiting [31], indicating
adequate nutritional vitamin D status despite low dietary
intakes (Table 2). The reduction in plasma 1,25(OH)2D3
Table 2. Average Usual Intakes (n 5 3 d) of Energy and
Nutrients Pertinent to the Study1,2
DRI3 Control Group Diabetic Group
Energy, kcal 2400 1950 6 480 1798 6 427
Protein, g 46 79.2 6 18.6 79.2 6 15.4
Lysine, g 2.64 2.3 6 1.4 2.9 6 1.4
Proline, g — 2.2 6 1.2 2.4 6 1.1
Vitamin D, mg 5 2.1 6 2.8 1.8 6 2.3
Vitamin B6., mg 1.3 1.2 6 0.7 1.3 6 0.8
Vitamin C, mg 75 87 6 68 114 6 88
Vitamin A, mg RAE 700 485 6 413 577 6 249
Vitamin K, mg 90 21.1 6 19 16.5 6 10.1
Magnesium, mg 320 178 6 93 169 6 60
Calcium, mg 1000 883 6 328 830 6 338
Past intakes5
Lactation 1000 762 6 183 633 6 204
Pregnancy 1000 731 6 311 608 6 167
Adolescence 1300 595 6 260 566 6 250
Phosphorus, mg 700 769 6 306 756 6 279
Iron, mg 18 13.3 6 4.3 12.5 6 4.9
Manganese, mg 1.8 1.9 6 0.9 2 6 1.3
Copper, mg 900 804 6 575 762 6 345
Zinc, mg 8 6.7 6 3.1 5.8 6 2.8
1 Mean 6 standard deviation. RAE, retinol activity equivalent.
2 None of the differences between groups were significant.
3 Dietary reference intakes (Food and Nutrition Board, Institute of Medicine,
2006 [25]).
4 On the basis of 38 mg/kg of body weight.
5 From frequency questionnaire.
Fig. 1. Number of cases (%) of low bone mineral density (T-score , 21.1) in healthy controls and in the diabetic group for the 10 lumbar and 3
proximal femur sites under investigation. When averaged over all sites, the proportion for each group differed significantly (p , 0.01). L 5 lumbar
vertebrae, Neck 5 femur neck, Ward’s 5 femur Ward’s triangle, Troch 5 femur trochanter.
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triggered an examination of possible explanatory factors. Iron,
a cofactor in the hydroxylation of 25(OH)D3 to 1,25(OH)2D3
in the kidneys, was not deficient, although its serum
concentration was significantly reduced (p , 0.05) in the
diabetic group (Table 3). As expected, a positive association
was found between 1,25(OH2)D3 and serum iron, but it was not
significant (Table 4). Reduction in the synthesis of this
hormone did not seem to result from defective renal function
either, since ACR was similar in both groups and well below
the threshold used to assess normal renal functioning [28]. In
addition, the correlation between 1,25(OH)2D3 and ACR was
not significant (Table 4).
Fig. 3 depicts data relative to biomarkers of osteoblast
functions and bone turnover. It shows, first of all, another
important biochemical finding: bone loss associated with
type 1 diabetes was not the result of bone resorption
(enhanced osteoclastic activity), as evidenced by no signif-
icant increase in urinary Dpd excretion (Fig. 3C). This
finding is in line with less osteoclastic activity, evidenced in
the IDDM group by the significant reduction of 1,25(OH)2D3
and with that of PTH (although not significant), the 2 major
calciotropic hormones having osteoclastic activity (Table 3).
However, there was less bone formation, as it usually occurs
when activity and/or functions of osteoblasts are reduced.
This cellular impairment was confirmed by significant
suppressions in OC (p , 0.01; Fig. 3B) and IGF-I (p ,
0.001; Table 3). In contrast, the expression of bALP
(Fig. 3A), another protein by-product of osteoblasts, normal-
ly reduced when there is less bone formation (at least in
nondiabetic subjects), was induced (p , 0.01) in the diabetic
group. This finding makes sense considering that total ALP
activity (from all cells, i.e., from liver, intestine, and bone)
was also significantly increased (Table 3). The correlation
between total ALP and bALP was highly significant (p ,
0.001; Table 4). No significant correlation was found
between this ALP isoenzyme and serum calcium. Circulating
IGF-I levels were not significantly correlated with the two
bone formation markers.
Fig. 2. Bone mineral density at the spine and femur in healthy controls and the diabetic group. Mean 6 standard deviation. L 5 lumbar vertebrae,
Neck 5 femur neck, Ward’s 5 femur Ward’s triangle, Troch 5 femur trochanter, Dia 5 femur diaphysis. ** p , 0.01, * p , 0.05.
Table 3. Biochemical Data Relevant to Bone Metabolism1
Reference Values2 Control Group Diabetic Group
Serum calcium, mmol/L 2.02–2.60 2.27 6 0.07 2.32 6 0.09*
Serum adjusted calcium,3 mmol/L — 2.32 6 0.07 2.40 6 0.80***
Serum phosphorus, mmol/L 0.9–1.81 1.15 6 0.16 1.07 6 0.16
Serum iron, mmol/L .5 21.6 6 7.8 17.1 6 6.6**
Serum iPTH, pmol/L 1.5–7.6 4.66 6 1.85 4.00 6 1.88
Plasma 25(OH)D3, nmol/L .50
4 78.6 6 30.2 72.8 6 26.6
Plasma 1,25(OH)2D3, pmol/L 42–169
5 132 6 48 94 6 23***
Plasma IGF-I, mg/L .706 120 6 47 79 6 31***
Serum total ALP, U/L 37–112 64.0 6 9.3 74.6 6 18.8**
1 Mean 6 standard deviation. iPTH 5 intact parathyroid hormone, IGF-I 5 insulin-like growth factor-I, ALP 5 alkaline phosphatase.
2 Reference values from our laboratories, except where otherwise specified.
3 Adjusted for albumin according to Berry et al., 1973 [29].
4 Calvo and Whiting, 2003 [31].
5 Konradsen et al., 2008 [32].
6 Donovan et al., 1991 [30].
*** p , 0.001.
** p , 0.01.
* p , 0.05.
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Interestingly, all significant biochemical changes found in
the diabetic group that were directly related to bone
metabolism were significantly correlated with HbA1c, indicat-
ing a direct effect of the disease.
DISCUSSION
BMD and Occurrence of Low BMD
The present study showed, first, that the IDDM group had
significantly lower BMD at the spine, particularly at the least
dense vertebra [33], and femur Ward’s triangle. The occur-
rence of osteopenia/osteoporosis was almost double among
subjects with diabetes. Despite its small sample size, this study
has reached the same conclusion as heterogeneous larger
studies because of its rigorous design in terms of subjects’
recruitment and consequent homogeneity within and between
groups, except for the presence of the disease. This
investigation of a well-defined cohort of IDDM women with
diabetes and healthy controls is of particular interest because
of its focus on a specific and significant time point in the life
cycle, that is, the first decade following peak bone mass.
Participants were eumenorrheic and not taking estrogen (oral
contraceptives); they were not too young to ensure that peak
bone mass had been reached and not premenopausal to avoid
irregular menstrual cycle. The study was also designed to
minimize other important BMD confounders such as body
frame and weight, physical activity, and parity. The disease in
the patient group was well monitored at the time of the study,
without known renal complication, as self-reported and
documented on the basis of ACR. There was no indication
of anemia (a sign of an advanced stage of the disease) in both
groups; protein intakes and nutritional status were adequate.
Table 4. Pertinent Correlations between Blood Biochemical Data in the Diabetic Group1
HbA1c IGF-I bALP Calcium 1,25(OH)2D3 PTH ACR
IGF-I 20.3989**
Total ALP +0.5038** +0.6071***
bALP +0.3784** 20.0170
Osteocalcin 20.4214** +0.0620 20.1819 +0.1679 +0.2701
1,25(OH)2D3 20.5693
** +0.0734 20.1205
iPTH 20.4683** +0.1668 20.5700***
Calcium +0.3962** 20.0117
Iron 20.2972* +0.1808
1 Values are correlation coefficients (r). HbA1c 5 glycosylated hemoglobin, IGF-I 5 insulin-like growth factor-I, bALP 5 bone-specific alkaline phosphatase (ALP),
Calcium 5 serum calcium adjusted for albumin, iPTH 5 intact parathyroid hormone, ACR 5 urinary albumin/creatinine ratio.
*** p , 0.001.
** p , 0.01.
* p , 0.05.
Fig. 3. Biomarkers of osteoblast functions and bone turnover in healthy controls and the diabetic group: (A) osteoblast functions, assessed by plasma bone
alkaline phosphatase (bALP); (B) bone formation, assessed by plasma concentration of osteocalcin; and (C) bone resorption, assessed by urinary excretion
of deoxypyridinoline (Dpd). The reference range for each biomarker is indicated by the shaded area. Mean 6 standard deviation. ** p , 0.01.
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Regarding the prevalence of bone complication in IDDM,
contradictory data have been reported in the literature,
depending on the criteria used, age, gender, and clinical
profile of patients. The number of cases (31%) with low BMD
(osteopenia and osteoporosis combined) in the present study
was lower than that reported by Kayath et al. [6]. Their cohort
was heterogeneous (as is often the case in bone studies) and
included young black and white people, of both genders, who
did not have full closure of long bone epiphyses and had not
reached their peak bone mass. The age of their female patients
varied widely (21–55 years) as did their hormonal status: some
were near or at menopause (estrogen deficiency) or on oral
(estrogen) contraceptives. In the study of Kemink et al. [12], a
high proportion (57%) of diabetic women were diagnosed with
osteopenia. In the study by Munoz-Torres et al. [36] composed
of 97 female and male IDDM patients with complications and
risk factors of osteoporosis, and whose age varied between 20
and 56 years, 20% of all diabetic subjects met the WHO
diagnostic criteria for osteoporosis.
Cellular Development and Functions of Osteoblasts
Although there seems to be a consensus on the negative
effect of IDDM on BMD, human studies on the coexistence of
potential mechanism(s) involving both cellular and circulating
levels are limited and conflicting. Serum total ALP, whose
activity includes bone and other cells, namely, from the liver
and intestine, is often increased in bone disorders. It was found
to be elevated in the present study, as shown by other
investigators [8,37]. With hepatic and renal functions being
similar in both groups, based on blood and urine tests, we
could presume that this observation referred to a bone origin.
As reported by Kemink et al. [12], bALP in the present study
was closely correlated with total ALP.
The significant coupled reductions of OC and IGF-I
observed in our study strongly confirmed a cellular bone
abnormality in IDDM patients. The reduction in IGF-I, an
important factor responsible for the final maturation of
osteoblasts, is in agreement with other reports [7,12,15,38].
Chronic hyperglycemia may indeed alter osteoblast differen-
tiation and maturation [39,40]. Using a diabetic rat model,
Verhaeghe et al. [41] found that osteoblast activity was
decreased.
Bone-specific ALP, also synthesized by osteoblasts, was
found to be significantly elevated in the IDDM group. Bouillon
et al. [15], on the other hand, reported normal bALP levels in
adult patients with IDDM. The imbalance of bone formation
markers (increased ALP and decreased OC) observed in the
present study is consistent with Botolin and McCabe’s [42]
findings from their animal model of diabetes. These investi-
gators demonstrated that the osteoblast response to chronic
hyperglycemia was expressed by an induction of ALP and
suppression of OC. This imbalance appears to be characteristic
of the bone complication of IDMM and reflects an impairment
in osteoblast differentiation and maturation. During develop-
ment, osteoblasts undergo a series of differentiation stages,
such as proliferation, matrix development, and matrix
mineralization. bALP activity is expressed early in the
development of osteoblasts, reaches a maximum during the
phase of matrix maturation, and is down-regulated during late
stages of matrix mineralization [43]. In their in vitro study,
Balint et al. [44] observed a significantly higher level of ALP
in cells incubated in the presence of high glucose concentra-
tion. At the end of the experimental period, the total amount of
calcium uptake into the glucose-treated cells was almost half
of control cell cultures; in other words, it took significantly
longer to deposit the same amount of calcium.
In the present study, a defective collagen network was ruled
out on the basis of adequate plasma supply of vitamin B6, a
coenzyme in extracellular matrix maturation (data not shown).
However, there was certainly inefficiency of the bone matrix to
mineralize as a result of incompetent osteoblasts to synthesize
OC and collagen involved in the process, as shown by an
experimental animal model [39]. Using the SRXRF micro-
probe technique and a rat model of diabetic osteoporosis, Fei et
al. [45] demonstrated that calcium content in bone (femur) was
reduced. These findings are in accordance with bone
densitometry studies in IDDM patients and the in vitro study
by Balint et al. [44].
Biomarkers of Bone Turnover
Although Miazgowski and Czekalski [13] failed to
demonstrate that diabetic osteopenia was influenced by the
duration of the disease or its metabolic control, poor glycemic
control has metabolic effects, such as acidosis and hypercal-
ciuria, that can lead to bone resorption, according to Bouillon
[16]. In the present study, the IDDM group did not exhibit
accrued bone resorption compared with healthy controls;
urinary Dpd excretion, used as the specific marker of bone
resorption, was not significantly greater. There are only a few
reports on pyridinoline and Dpd in IDDM; these collagen
cross-links are formed during the final stage of extracellular
collagen maturation. Their measurements in urine have been
shown to provide the most valid clinical markers of collagen
degradation [46]. Since Dpd has a much more restricted tissue
distribution and is primarily located in bone collagen, it seems
to be a more specific and sensitive marker of bone resorption
than pyridinoline [46].
First, the lack of biochemical evidence of bone resorption
in our IDDM patient group confirmed good glycemic control
(HbA1c close to 7.5%), a selection criterion specified in the
study design. Second, in agreement with animal models
[39,47] and human studies [11–13], this finding confirmed
that IDDM-induced bone loss results from a defect in
formation in contrast to menopausal bone loss, characterized
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by an accrued resorption due to estrogen deficiency. The fact
that both osteoclast-stimulating calciotropic hormones
1,25(OH)2D3 and PTH were not increased reinforces this
conclusion, which is consistent with the robust histomorpho-
metric analyses of Goodman and Hori [48]. These investigators
have characterized diabetic osteopenia as of a low-turnover
type, suggesting that it may be considered a slow bone-
remodeling disorder. In a less robust biochemical study,
Gallacher et al. [8] observed that IDDM was associated with
bone resorption in women whose mean age was 32 years
(range, 23–42 years). But their finding was based on urinary
hydroxyproline excretion as the collagen biomarker of
resorption. This marker is not commonly used anymore
because of its lack of sensitivity.
Serum Calcium Homeostasis and Vitamin D
Metabolism
A biochemical abnormality characterizing IDDM-induced
bone disorder in the present study was the highly significant
elevation of serum calcium concentration, particularly after
adjustment for albumin. This alteration in calcium homeostasis
seems to be contradicting in a metabolic context of lower
intestinal calcium absorption due to renal reduction of
1,25(OH)2D3. Furthermore, plasma concentration of the hepatic
precursor [25(OH)D3], used as an indicator of vitamin D
nutritional status, and current and past dietary calcium intakes
during adolescence, pregnancy, and lactation were similar in
both groups. Serum iron, which may have contributed to the
reduction of 1,25(OH)2D3 owing to its role as a cofactor in the
hydroxylation of 25(OH)D3, was significantly reduced in the
IDDM group. However, the absence of a significant correlation
between these 2 parameters makes this explanation unlikely.
This finding should not be interpreted to mean that the
association between IDDM and iron is not relevant. Quite the
contrary, in severe iron deficiency, not only does 1,25(OH)2D3
concentration decrease, but there is also less bone formation
through reductions of OC and IGF-I [49].
Serum calcium concentration is closely controlled by
hormones, and an elevation would inhibit PTH release, perhaps
explaining why serum PTH level was lower (although not
significantly) in our IDDM group. However, the inverse
correlation was found to be significant. A state of functional
hypoparathyroidism has been described in patients with IDDM
[50]. This could be another indirect skeletal sequela of the
disease. In the oral glucose load study on healthy women by
D’Erasmo et al. [51], PTH was suppressed. Balint et al. [44]
postulated, from their in vitro model of the inhibitory effect of
glucose on osteoblastic calcium deposition, that improvement
of osteoblast mineralization function could lower serum
calcium concentration, and thus ameliorate the renal hyper-
calciuria status found in IDDM patients with poor glycemic
control.
In brief, the present study highlighted the persistence and
magnitude of IDDM-induced bone disorder despite good
glycemic control and apparent absence of renal complications.
Both lumbar vertebrae and femur were affected. The
underlying pathogenic mechanisms that were evidenced are
as follows: (1) low bone formation due to diminished activity/
functions of osteoblasts and uncoupled bone formation and
resorption and (2) independent alterations in serum calcium
homeostasis and vitamin D metabolism. The interpretation of
bALP as a marker of bone formation in investigations on
IDDM-induced bone complication warrants caution. Other
rigorous large studies are needed to address this issue.
Although the complete picture of the pathogenesis of bone
disease in IDDM has not been revealed, the present study
identified a real need to examine and follow up diabetic
patients for the risk of osteoporosis and related fractures at an
early stage. It also underlined the importance of a well-
designed protocol that will allow a minimum of confounding
variables and include the clinical profile combined with
nutritional status evaluation in bone investigations.
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